연구성과로 돌아가기

2025 연구성과별 연구자 정보 (361 / 1187)

※ 현재 Web of Science 저자 정보만 집계되어 있습니다.
※ 컨트롤 + 클릭으로 열별 다중 정렬 가능합니다.
Excel 다운로드
Document Title Author Full Name Author Short Name Index Corresponding Address ResearcherID ResearcherID Author Name ORCID ORCID Author Name Related Email
Efficacy and safety of epaminurad, a potent hURAT1 inhibitor, in patients with gout: a randomized, placebo-controlled, dose-finding study Lee, Shin-Seok Lee, SS 11 Chonnam Natl Univ Med Sch & Hosp, Dept Internal Med, Div Rheumatol, Gwangju, South Korea drsong@cau.ac.kr;
Efficacy and safety of epaminurad, a potent hURAT1 inhibitor, in patients with gout: a randomized, placebo-controlled, dose-finding study Kim, Hyun Ah Kim, HA 12 Hallym Univ, Sacred Heart Hosp, Dept Internal Med, Div Rheumatol, Anyang, South Korea drsong@cau.ac.kr;
Efficacy and safety of epaminurad, a potent hURAT1 inhibitor, in patients with gout: a randomized, placebo-controlled, dose-finding study Hwang, Jiwon Hwang, J 13 Kyung Hee Univ, Kyung Hee Univ Hosp, Coll Med, Dept Rheumatol, Seoul, South Korea drsong@cau.ac.kr;
Efficacy and safety of epaminurad, a potent hURAT1 inhibitor, in patients with gout: a randomized, placebo-controlled, dose-finding study Suh, Chang-Hee Suh, CH 14 Ajou Univ, Sch Med, Dept Rheumatol, Suwon, South Korea drsong@cau.ac.kr;
Efficacy and safety of epaminurad, a potent hURAT1 inhibitor, in patients with gout: a randomized, placebo-controlled, dose-finding study Han, Seungwoo Han, S 15 Kyungpook Natl Univ, Sch Med, Dept Internal Med, Div Rheumatol, Daegu, South Korea drsong@cau.ac.kr;
Efficacy and safety of epaminurad, a potent hURAT1 inhibitor, in patients with gout: a randomized, placebo-controlled, dose-finding study Choe, Jung-Yoon Choe, JY 16 Daegu Catholic Univ, Sch Med, Dept Internal Med, Div Rheumatol, Daegu, South Korea drsong@cau.ac.kr;
Efficacy and safety of epaminurad, a potent hURAT1 inhibitor, in patients with gout: a randomized, placebo-controlled, dose-finding study Yoo, Wan-Hee Yoo, WH 17 Jeonbuk Natl Univ, Med Sch, Dept Internal Med, Div Rheumatol, Jeonju, South Korea drsong@cau.ac.kr;
Efficacy and safety of epaminurad, a potent hURAT1 inhibitor, in patients with gout: a randomized, placebo-controlled, dose-finding study Song, Jung Soo Song, JS 18 교신저자 Chung Ang Univ, Sch Med, Dept Internal Med, Div Rheumatol, 102 Heukseok Ro, Seoul 06973, South Korea drsong@cau.ac.kr;
Efficacy and safety of safinamide in Parkinson's disease patients with motor fluctuations without levodopa dosage escalation over 18 weeks: KEEP study Oh, Eungseok Oh, E 1 Chungnam Natl Univ, Coll Med & Hosp, Dept Neurol, Daejeon 301721, South Korea AAL-8935-2020 Oh, Eungseok jsbaik@paik.ac.kr;
Efficacy and safety of safinamide in Parkinson's disease patients with motor fluctuations without levodopa dosage escalation over 18 weeks: KEEP study Cheon, Sang-Myeong Cheon, SM 2 Dong A Univ, Sch Med, Dept Neurol, Busan 602705, South Korea jsbaik@paik.ac.kr;
Efficacy and safety of safinamide in Parkinson's disease patients with motor fluctuations without levodopa dosage escalation over 18 weeks: KEEP study Cho, Jin Whan Cho, JW 3 Sungkyunkwan Univ, Sch Med, Sch Med, Dept Neurol, Seoul, South Korea jsbaik@paik.ac.kr;
Efficacy and safety of safinamide in Parkinson's disease patients with motor fluctuations without levodopa dosage escalation over 18 weeks: KEEP study Sung, Young Hee Sung, YH 4 Gachon Univ, Coll Med, Gil Med Ctr, Dept Neurol, Incheon, South Korea jsbaik@paik.ac.kr;
Efficacy and safety of safinamide in Parkinson's disease patients with motor fluctuations without levodopa dosage escalation over 18 weeks: KEEP study Kim, Joong-Seok Kim, JS 5 Catholic Univ Korea, Seoul St Marys Hosp, Coll Med, Dept Neurol, Seoul 150713, South Korea jsbaik@paik.ac.kr;
Efficacy and safety of safinamide in Parkinson's disease patients with motor fluctuations without levodopa dosage escalation over 18 weeks: KEEP study Shin, Hae-Won Shin, HW 6 Chung Ang Univ Hosp, Dept Neurol, Seoul, South Korea jsbaik@paik.ac.kr;
Efficacy and safety of safinamide in Parkinson's disease patients with motor fluctuations without levodopa dosage escalation over 18 weeks: KEEP study Kim, Jong-Min Kim, JM 7 Seoul Natl Univ, Bundang Hosp, Coll Med, Dept Neurol, Seongnam, South Korea jsbaik@paik.ac.kr;
페이지 이동: